Stem cell therapy for COVID-19 pneumonia
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is a highly contagious microorganism, and despite substantial investigation, no progress has been achieved in treating post-COVID complications. However, the virus has made various mutations and has spread around the world....
Main Authors: | Maziar Malekzadeh Kebria, Peiman Brouki Milan, Noshad Peyravian, Jafar Kiani, Soheil Khatibi, Masoud Mozafari |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer
2022-02-01
|
Series: | Molecular Biomedicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43556-021-00067-8 |
Similar Items
-
CRISPR-Associated (CAS) Effectors Delivery via Microfluidic Cell-Deformation Chip
by: Noshad Peyravian, et al.
Published: (2021-06-01) -
Mesenchymal stem/stromal cell-based therapies for severe viral pneumonia: therapeutic potential and challenges
by: C. H. Masterson, et al.
Published: (2021-12-01) -
Human Olfactory Mucosa Stem Cells Delivery Using a Collagen Hydrogel: As a Potential Candidate for Bone Tissue Engineering
by: Sara Simorgh, et al.
Published: (2021-07-01) -
Evaluation of Treatment with a single (400mg) versus double dose (800mg) of Tocilizumab in Acute Respiratory Distress Syndrome Associated with COVID-19Pneumonia
by: Mehmet Kabak, et al.
Published: (2022-01-01) -
Bone Tissue Engineering Using Human Cells: A Comprehensive Review on Recent Trends, Current Prospects, and Recommendations
by: Saeid Kargozar, et al.
Published: (2019-01-01)